Department of Medicinal and Biological Chemistry

Katherine A. Wall, Ph.D.

Wall

Professor and Chair
Department of Medicinal and Biological Chemistry


419.383.1943 Phone
Frederic and Mary Wolfe 284A
katherine.wall@utoledo.edu

Education

B.S., 1971 Montana State University
Ph.D., 1977 University of California at Berkeley
Damon Runyon-Walter Winchell
Cancer Research Fellowship
1977-79
Massachusetts Institute of Technology
NIH Fellowship, 1980-82 University of Chicago
Visiting Investigator 2000-01 University of Michigan
Visiting Professor 2010 University of Rochester Medical Center

Immunology and biochemistry; synthetic glycoprotein anti-cancer and anti-bacterial vaccines and their targeting; NAADP actions in lymphocytes, design of immunomodulatory drugs.

Research Interests

I have two major projects ongoing in my laboratory.

1) Glycopeptide-Based Vaccines
This project is a collaboration with Dr. Steve Sucheck of the UToledo Department of Chemistry and Biochemistry. We have been studying the immune response of mice to cancer vaccines containing synthetic cancer glycopeptide antigens with a covalently attached rhamnose epitope. This is designed to take advantage of anti-rhamnose anitbodies that occur naturally in humans and can be generated in mice. We are developing additional synthetic vaccines against bacterial infections that take advantage of antibody targeting. 

2) CD38 and NAD Metabolites in Lymphocyte Signaling
I have a longstanding interest in the role of NAD metabolites in lymphocyte function. My lab is continuing a collaboration with Dr. James Slama to examine the role of NAADP, a highly potent calcium mobilizing agent, in lymphocyte signaling and function.

Representative Publications

  1. Synthesis and immunological evaluation of a single molecular construct MUC1 vaccine containing I-rhamnose repeating units. K. Hossain, A. Vartak, S. J. Sucheck, and K. A. Wall. Molecules 25 (14): 3137, 2020. PubMedID: 32659971
  2. Development of a bioconjugate platform for modifying the immune response of autoreactive cytotoxic T lymphocytes involved in type 1 diabetes. N. Nandedkar-Kulkarni, A. Vartak, S. Sucheck, K. Wall, A. Quinn, M. Morran, and M. McInerney. Bioconjugate Chemistry 30: 2049-2059, 2019. PubMedID: 31274300
  3. Use of dendritic cell receptors as targets for enhancing anti-cancer immune responses. M. K. Hossain and K. A. Wall. Cancers 11 (3): 2019. PubMedID: 30909630
  4. Liposomal Fc domain conjugated to a cancer vaccine enhances both humoral and cellular immunity. M. K. Hossain, A. Vartak, S. J. Sucheck, and K. A. Wall. ACS Omega 4: 5204-5208, 2019. PubMedID: 30949616
  5. Augmenting vaccine immunogenicity through the use of natural human anti-rhamnose antibodies. M. K. Hossain, A. Vartak, P. Karmakar, S. J. Sucheck, and K. A. Wall. ACS Chem. Biol. 13: 2130-2142, 2018. PubMedID: 29916701
  6. Immunological evaluation of recent MUC1 glycopeptide cancer vaccines. M. K. Hossain and K. A. Wall. Vaccines 4 (3): 25, 2016. PubMedID: 27472370
  7. Nicotinic acid adenine dinucleotide plays a critical role in naïve and effector murine T cells but not natural regulatory T cells. R. A. Ali, C. Camick, K. Wiles, T. F. Walseth, J. T. Slama, S. Bhattacharya, D. R. Giovannucci, and K. A. Wall. J. Biol. Chem. 291: 4503-4522, 2016. PubMedID: 26728458
  8. Synthesis of a liposomal MUC1 glycopeptide-based immunotherapeutic and evaluation of the effect of L-rhamnose targeting on cellular immune responses. P. Karmakar, K. Lee, S. Sarkar, K. A. Wall, and S. J. Sucheck. Bioconjugate Chem. 27: 110-120, 2016. PubMedID: 26595674
  9. Synthesis of α-L-rhamnosyl ceramide and evaluation of its binding with anti-rhamnose antibodies.  D. E. Long, P. Karmakar, K. A. Wall, and S. J. Sucheck. Bioorg. & Med. Chem. 22: 5279-5289, 2014. PubMedID: 25172148
  10. Activity of nicotinic acid substituted nicotinic acid adenine dinucleotide phosphate (NAADP) analogs in a human cell line: difference in specificity between human and sea urchin NAADP receptors.  R. A. Ali, T. Zhelay, C. Trabbic, T. F. Walseth, J. T. Slama, D. R. Giovannucci, and K. A. Wall.  Cell Calcium 55: 93-103, 2014. PubMedID: 24439527
  11. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into L-rhamnose displaying liposomes.  S. Sarkar, A. Salyer, K. A. Wall, and S. Sucheck.  Bioconjugate Chem. 24: 363–375, 2013. PubMedID: 23444835
  12. Synthesis of a single molecule L-rhamnose-containing three component vaccine and evaluation of antigenicity in the presence of anti-L-rhamnose antibodies.  S. Sarkar, S. A. Lombardo, D. N. Herner, R. S. Talan, K. A. Wall, and S. J. Sucheck.  J. Amer. Chem. Soc. 132: 17236-17246, 2010. PubMedID: 21080675
  13. Cowpea mosaic capsid: a promising carrier for the development of carbohydrate based antitumor vaccines. A. Miermont, H. Barnhill, E. Strable, X. Lu, K. A. Wall, Q. Wang, M. G. Finn, and X. Huang. Chemistry - A European Journal 14: 4939-4947, 2008. PubMedID: 18431733
Last Updated: 8/6/20